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Evidence on the use of paracetamol in febrile children
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Abstract Antipyretics, including acetaminophen (paracetamol), are prescribed commonly in children with pyrexia, despite minimal
evidence of a clinical benefit. A literature review was performed by searching Medline and the Cochrane databases for research papers
on the efficacy of paracetamol in febrile illnesses in children and adverse outcomes related to the use of paracetamol. No studies showed
any clear benefit for the use of paracetamol in therapeutic doses in febrile children with viral or bacterial infections or with malaria. Some
studies suggested that fever may have a beneficial role in infection, although no definitive prospective studies in children have been
done to prove this. The use of paracetamol in therapeutic doses generally is safe, although hepatotoxicity has occurred with
recommended dosages in children. In developing countries where malnutrition is common, data on the safety of paracetamol are
lacking. The cost of paracetamol for poor families is substantial. No evidence shows that it is beneficial to treat febrile children with
paracetamol. Treatment should be given only to children who are in obvious discomfort and those with conditions known to be painful.
The role of paracetamol in children with severe malaria or sepsis and in malnourished, febrile children needs to be clarified.
Keywords Acetaminophen/pharmacology; Fever/drug therapy; Child; Virus diseases/drug therapy; Bacterial infections/drug
therapy; Malaria, Falciparum/drug therapy; Febrile seizures/drug therapy; Treatment outcome; Review literature; Meta-analysis
(source: MeSH, NLM ).
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Introduction
Fever is a common symptom of childhood illness in both
developed and developing countries, andmuch time and effort is
spent on attempts to reduce high temperatures in young children.
Although the disease process that leads to fever may be harmful,
no convincing evidence shows that fever itself is harmful.
Temperatures that exceed the maximum of the normal febrile
range (41 oC) are usually caused by heat stroke or brain injury (1)
and so do not respond to antipyretics (2). Some evidence in fact
shows that fevermay bebeneficial in enhancing thehost response
to infection (3).Despite this,many parents and physicians believe
that antipyretic treatment improves febrile children’s comfort
and behaviour. Antipyretics are prescribed commonly, therefore,
despite minimal data on their clinical benefit.
Few prospective human studies have documented
whether antipyretics have any clinically relevant adverse
effects. Some animal studies have shown that fever helps
survival during infection, and that antipyresis increases
mortality (4–7). Growing evidence shows the potential for
hepatotoxicity in children given multiple therapeutic or
subtherapeutic doses of acetaminophen (paracetamol) (8–
10). Product information recommends a maximum daily dose
of 60 mg/kg, but it is not uncommon for children to receive
90 mg/kg/day in hospital (11).
Throughout the world, parents and health professionals
routinely treat fever in young children. The current guidelines
of WHO on the management of fever recommend the use of
paracetamol for children with a fever539 oC (12). This article
aims to summarize existing evidence on the rational use of
paracetamol in febrile children, highlight the deficiencies in
current knowledge, and make recommendations for further
research.
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Methods
We searchedMedline and the Cochrane databases from 1966–
2002 with the search term paracetamol in combination with:
fever, children, and trial; sepsis; malaria; fever and hospital
discharge; febrile convulsion and trial; hepatotoxicity; adverse
events and review; fever and parental anxiety; or comfort and
trial. The same search was performed with the search term
‘‘acetaminophen’’ exchanged with ‘‘paracetamol’’. The search
was limited to those articles that involved children and were in
the English language only. As few randomized control trials
were identified, other references from these articles were
reviewed and other experimental study designs included. A
total of 17 studies were identified.
Results
Paracetamol and viral infections
Few reports exist on the potential risks and benefits of giving
paracetamol to children with viral infections. A randomized
trial of paracetamol (10–15 mg/kg/dose every four hours)
versus placebo in 225 febrile children with non-bacterial
infections showed there was no significant difference between
treated and placebo groups in mean duration of fever or other
symptoms (13). Parents of children treated with paracetamol
rated their children as being slightly more active and alert than
those treated with placebo. No significant differences existed,
however, in mood, comfort, appetite, or fluid intake. Another
randomized trial that compared paracetamol (10 mg/kg/dose
four times per day for four days) with placebo in 72 children
with varicella infection showed no significant differences in
durations of symptoms (itching, activity, or appetite) but a
longer time to total crusting of lesions in children who received
paracetamol than in those who received placebo (14).
Paracetamol and bacterial infections
Limited data exist on the use of paracetamol in sepsis in
humans, particularly children. Despite this, antipyretic therapy
commonly is administered to patients with bacterial sepsis (15).
A mixed retrospective and prospective study of 180 hospita-
lized children (ages not stated) with uncomplicated proven
bacterial infections were assessed for the effect of paracetamol
treatment on duration of hospital stay (16). Patients were
divided into six groups of 30 children. Children with
pneumococcal pneumonia, staphylococcal cellulitis, or Hae-
mophilus influenzaemeningitis who received at least two doses of
paracetamol were compared with counterparts who received
one or no doses of paracetamol. Three of the children received
both aspirin and paracetamol, however, and three received only
aspirin. No statistically significant difference was seen in
duration of hospital stay between any of the clinical groups
who received paracetamol and those who did not after
adjustmentsweremade for age, temperature on admission, and
the number of doses received (16). This study, however, only
described the number of doses of paracetamol received rather
than the actual dose received.
Two retrospective (and therefore non-randomized) stu-
dies have been published. Administration of paracetamol (dose
not stated) at the time of blood culture was an independent
predictor of survival in patients with Escherichia coli bacteraemia
(17) andPseudomonas aeruginosa sepsis (18). The use of paracetamol
and improvement in survival did not correlate, however, with
reductions in core temperature. It should be noted that as these
studies are not randomized the effect of paracetamol on survival
might only represent a proxy for the ability of the individual to
mount an effective response to infection.
Many studies suggest that fever is a beneficial response
to bacterial infection. Fever has been reported to be associated
with increased survival in patients with spontaneous bacterial
peritonitis (19, 20) and polymicrobial sepsis (21). A prospective
study of 748 children with severe pneumonia in Papua New
Guinea found mortality rates of 29% in afebrile malnourished
children and 12% in febrile malnourished children; no such
difference was found in well-nourished children with severe
pneumonia (22). In three other prospective studies of sepsis,
hypothermia was present in about 10% of adults surveyed and
was associated with a greater than two-fold higher mortality
than the presence of fever (23, 24). Several retrospective
studies confirmed that human survival after serious infection is
reduced in patients with hypothermia or in those who fail to
generate a fever (23–26).
A common rationale for reducing fever is to prevent
tissue injury caused by elevated core temperatures. No
published reports, however, show cytotoxicity from tempera-
tures within the febrile range that are associated with infections
(15). Another rationale for reducing fever is to decrease the
metabolic demands associated with the febrile response, which
may be important in patients with cardiac or respiratory failure.
In one study, 12 critically ill patients with sepsis were treated
with paracetamol. Oxygen consumption, carbon dioxide
production, and cardiac output were reduced by 18%, 20%,
and 23%, respectively (27).
Paracetamol and malaria
Fever is a striking clinical feature of malaria. The biological role
of fever in malaria is unclear, although some recent evidence
shows that itmay be beneficial (28). Tumour necrosis factor is an
important mediator of malarial fever (29, 30), and experimental
data suggest that both tumour necrosis factor and fever have
antiparasitic properties (31, 32). Fifty children fromGabon with
non-severe Plasmodium falciparum malaria were randomized to
receive mechanical antipyresis either alone or in combination
with paracetamol (10–15 mg/kg/dose per rectum, every four
hours while febrile) (33). Time to parasitic clearance was
significantly longer in the paracetamol group. As no difference
was found in the course of fever between the two groups,
however, the difference in parasite clearance may not be
attributable to fever per se. Levels of tumour necrosis factor
(TNF) were reduced in the paracetamol group, whereas
concentrations of interleukin (IL-6) were not affected. This
suggests that paracetamol has more of an immunomodulatory
effect on TNF than on IL-6. As TNF has an important
antiparasitic role in malaria, the longer time to parasite clearance
in the paracetamol group was postulated to be due to the
significantly decreased production of TNF and oxygen radicals
in the paracetamol group (33).
Vomiting is a major problem in children with malaria, as
it interferes with the absorption of antimalarials. Previous
studies suggested that febrile patients are more likely to vomit
mefloquine, so antipyresis might improve the management of
malaria (34). A randomized controlled trial on the western
border of Thailand in 321 childrenwith non-severeP. falciparum
malaria assessed the effect of early antipyresis on the
proportion of children who vomited (35). Children were
randomized to receive acetaminophen (15 mg/kg/dose) and
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tepid sponging either before or at the same time asmefloquine.
Reduction of fever with acetaminophen and tepid sponging
before mefloquine was given did not reduce the incidence of
early vomiting, which was the same for both groups (35).
Paracetamol and febrile convulsions
Many clinicians treat fever with paracetamol to prevent febrile
convulsions in susceptible children. Febrile convulsions occur in
4% of children, however, and they are usually self-limiting.
Moreover, no evidence shows that antipyretic treatment reduces
the risk of febrile convulsions. In a randomized controlled trial,
157 children enrolled after their first febrile convulsion were
followed for two years (36). Children were assigned to receive
either one dose of rectally administered diazepam followed by
oral doses three times daily for the first two days if the
temperature was >38.5 oC or a placebo. In addition, each
subsequent febrile episode was assigned randomly to receive
paracetamol or placebo. Neither paracetamol nor diazepam
made a difference to the recurrence of convulsions (36). This
study had 80% power to detect a statistically significant result
with the given sample size (36). Another controlled trial studied
the antipyretic effect of paracetamol in 104 children: one group
received regular paracetamol and the other sporadic paraceta-
mol. Prophylactic paracetamol was no more effective than
sporadic paracetamol in preventing fever or early recurrence of
febrile convulsions (37).
Adverse events
Although paracetamol generally is regarded as a very safe
antipyretic drug, liver failure is awell-recognized consequence of
paracetamol overdose (9, 10, 38–40). Recent case reports have
suggested that liver failure can be caused by the administration
of multiple doses of paracetamol that are only just greater than
the recommended maximum dose (8). The largest paediatric
series of hepatotoxicity secondary to paracetamol reviewed
cases reported to the Food and Drug Administration and
National PoisonsCenter in theUS over a 15-year period (9). This
review documented 47 children aged between five weeks and
10 years who developed hepatotoxicity after taking doses of
paracetamol ranging between 60 and 420 mg/kg/day. The
duration of treatment ranged from one day to six weeks. The
mortality rate was high: half the children died (24 deaths), and
three survived after they received liver transplants. Six children
with hepatotoxicity had received doses of paracetamol within, or
only slightly above, the approved dose (4100 mg/kg/day) (9).
The total number of cases in this report was small compared
with the total number of children who were treated with
paracetamol; however, this study may under-represent the total
number of cases of hepatotoxicity, as it is likely that many less
severely affected were unreported.
In the same study, children who were febrile and acutely
malnourished had an increased risk of paracetamol-induced
hepatotoxicity (41). This is important, because paracetamol is
used in the developing world. There are sound theoretical
reasons why malnourished children may be at higher risk.
Reductions in caloric or protein intake combined with multiple
doses of paracetamol may have profound effects on sulfation,
glucuronidation, and glutathione production (41). In particular,
the presumed depletion of glutathione and impairment of the
glucuronidation pathway caused by fasting may also apply to
acutely ill children who are not eating. Repeated administration
of paracetamol may lead to further reductions in hepatic
glutathione, which may impair the biotransformation of
paracetamol and cause hepatotoxicity (9). The risk of
hepatotoxicity is increased if a child is aged under two years
and has repeated vomiting, diarrhoea, or poor fluid intake for
more that 24 hours, and if paracetamol has been given at a dose
590 mg/kg/day (9).
In contrast, a large randomized controlled trial of over
27 000 febrile children compared the risk of serious adverse
events between three groups randomized to receive acetami-
nophen (12 mg/kg/dose) or ibuprofen in one of two doses
(5 or 10 mg/kg/dose) (2). A median of 6–10 doses was
received over three days. The risk of hospitalization for any
reason during the four-week follow up period was 1.4%. The
risk of hospitalization for secondary study outcomes such as
asthma, bronchiolitis, vomiting, or gastritis did not differ
significantly between those who received paracetamol or
ibuprofen. These data indicate little risk of serious adverse
events that require hospitalization among febrile children
treated with low doses of paracetamol or ibuprofen (2). No
cases of hepatotoxicity were reported.
Costs
Fever is an extremely common symptom in children and a
frequent reason for attendance at paediatric emergency
departments. For poor families, the cost of a bottle of
paracetamol is substantial. Repeated febrile episodes in a
number of young children within a family may result in
considerable expense for an unnecessary medication. Using
United Nations Children’s Fund (UNICEF) prices, the cost of
a dose of paracetamol is US$ 0.50 for 100 ml for a 24 mg/ml
preparation (42).
In developing countries, prescribing practices may be
different. Infants and children may be given a quarter or half of
a 100 mg or 500 mg tablet of paracetamol. The UNICEF cost
of paracetamol tablets is less than that of syrup (US$ 0.0031
per 100 mg tablet and US$ 0.0061 per 500 mg tablet) (42),
however over- or under-prescribing becomes a problem. In
addition, little accuracy can be assured for a child of any weight
when a dose per kilogram of paracetamol is prescribed but only
500-mg tablets of paracetamol are available.
Discussion
Fever is one of the most common symptoms of illness in
childhood. The costs associated with the prescribing of
paracetamol are not trivial for many families. No studies show
any clear benefit for the use of paracetamol in therapeutic
doses in febrile children. A Cochrane Review was unable to
show a superior antipyretic effect with paracetamol compared
with placebo (43). Many of the studies in the Cochrane Review
used inadequate doses of paracetamol; this review therefore
provides inadequate evidence to support the proposition that
paracetamol is ineffective treatment for fever. Our literature
search was limited to English language articles, and therefore it
may have excluded some relevant articles in other languages.
Some studies suggest that fever may have a beneficial
role, although no definitive prospective studies in children
have been done to prove this. Hyperthermia is known to be
harmful if temperatures exceed 41 oC. Temperatures above the
usual febrile maximum (>41 oC) are usually caused by heat
stroke or brain injury (1) and so do not respond to antipyretics
(2). The paucity of data means it is difficult to make conclusive
recommendations on the rational use of paracetamol in febrile
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children, particularly those with comorbidities from develop-
ing countries.
Reports about the role of cytokines and the possible
beneficial or detrimental effects on clinical outcomes are
conflicting. Fever is due to the production of endogenous
pyrogens, including the cytokines IL-1, IL-6, TNF, interferon-b,
interferon-g, and prostaglandin E2. Exogenous pyrogens, such
as microbial products, stimulate macrophages to produce
endogenous pyrogens, which results in fever. In vitro and in
vivo experiments have raised the possibility of a protective effect
of the cytokines IL-1, IL-6, TNF-a, and interferon and therefore
the possibility that they enhance resistance to infection. This has
been shown in animal models for Plasmodia species (44–46),
Toxoplasma gondii (47), Leishmania major (48), Trypanosoma cruzi
(49), and Cryptosporidium species (50). These studies suggest,
therefore, that suppression of fever might be counterproduc-
tive. Other reports suggest, however, that for at least some
infections, these mediators may have a detrimental effect on
clinical outcomes. Emerging evidence from studies on Gram-
negative bacterial sepsis shows that these cytokines are
mediators of the clinical and humoral manifestations of
Gram-negative sepsis (51–52) and that detectable levels of IL-
1, IL-6, and TNF-a correlated inversely with survival (53).
From the limited data available, paracetamol in ther-
apeutic doses seems to offer little benefit for childrenwith viral
infections. A prospective, placebo-controlled trial of anti-
pyretic therapy in bacterial sepsis is needed to develop a
rational approach to treating fever in these patients. On the
basis of available data, we recommend that antipyretics be
withheld — at least during the early stages of sepsis. If febrile
children have cardiac or respiratory failure, paracetamol may
reduce oxygen consumption, carbon dioxide production, and
cardiac output (1). Recent but limited research suggests the
time to parasite clearance in non-severe malaria is longer in
children given paracetamol (33). Further studies are required,
however, to define the role of paracetamol in severe malaria.
For otherwise healthy children, the use of paracetamol in
therapeutic doses generally is safe, although hepatotoxicity has
occurred with recommended dosages in children — often
those with comorbidities. Data on the safety of paracetamol is
lacking for developing countries in which malnutrition is
common. Further research is recommended to determine the
safety of paracetamol in this population of sick, malnourished
children.
Paracetamol is often given to febrile children to improve
patient comfort. There is, however, a lack of well-designed
studies to quantify this. In a randomized trial of paracetamol
versus placebo in 225 febrile children with non-bacterial
infections, children treated with paracetamol were more likely
to be rated by their parents as having at least a one-category
improvement in activity (38% vs 11%; P= 0.005) and alertness
(33 vs 12%; P= 0.036), but no significant difference was noted
inmood, comfort, appetite, or fluid intake (13). The lack of any
significant improvement in behaviour and comfort with
paracetamol was emphasized by the inaccuracy of the parents’
‘‘guesses’’ at the end of the trial as towhich agent their child had
received: 45% correctly guessed paracetamol and 52% placebo
(13). Although clinicians have argued that administration of
paracetamol can be justified because it improves patient
comfort, no trials have adequately documented this benefit.
The relative costs of the benefits of symptomatic relief
versus the adverse effect of toxicity or the impact on illness
response have not been determined. Some evidence shows
that paracetamol may prolong patient discomfort by prolong-
ing the duration of illness. Childrenwith varicella infectionwho
were treated with paracetamol showed a longer time to total
crusting of lesions compared with those who received placebo
(14). This may prolong pruritis. In addition, patients with
malaria whowere treatedwith paracetamol had a longer time to
parasitic clearance (33).
The current WHO recommendations for the manage-
ment of fever in children include the use of paracetamol for
childrenwith fever of539 oC (12). Insufficient data, however,
support this recommendation. We recommend that health
professionals should not be encouraged to give antipyretics
routinely to febrile children. Treatment should only be given to
those children in obvious discomfort or those with known
painful conditions. The role of paracetamol in children with
severe malaria or sepsis and in sick, malnourished, febrile
children needs to be clarified further. n
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Re´sume´
Observations concernant l’utilisation du parace´tamol chez l’enfant fe´brile
Les antipyre´tiques, y compris le parace´tamol, sont prescrits
couramment chez l’enfant pyre´tique, malgre´ le peu d’arguments
qui sous-tendent son inte´reˆt clinique. Une mise au point
bibliographique a e´te´ effectue´e en recherchant les articles de
recherche dans les bases de donne´es Cochrane et Medline sur
l’efficacite´ du parace´tamol dans les affections fe´briles pe´diatriques
et les e´ve´nements inde´sirables associe´s a` son utilisation. Aucune
e´tude ne montre d’avantage manifeste du parace´tamol a` dose
the´rapeutique chez l’enfant fe´brile atteint d’infection virale ou
bacte´rienne ou de paludisme. D’apre`s certaines e´tudes, la fie`vre
semblerait meˆme avoir un effet be´ne´fique sur l’infection, bien
qu’aucune e´tude prospective de´finitive n’ait e´te´ re´alise´e chez
l’enfant pour tester cette hypothe`se. L’utilisation du parace´tamol a`
dose the´rapeutique est ge´ne´ralement sans danger ; des manifes-
tations d’he´patoxicite´ ont toutefois e´te´ observe´es a` la posologie
pe´diatrique recommande´e. Dans les pays ou` la malnutrition est
fre´quente l’innocuite´ du parace´tamol est mal connue. Pour les
familles pauvres, le couˆt du parace´tamol est conside´rable. Rien
n’indique l’inte´reˆt du traitement de l’enfant fe´brile par le
parace´tamol. Ce traitement ne devrait donc eˆtre administre´ qu’a`
l’enfant manifestement incommode´ ou dont l’affection est
douloureuse. La place du parace´tamol chez l’enfant atteint de
paludisme grave ou d’infection ainsi que chez l’enfant mal nourri et
fe´brile demande a` eˆtre clarifie´e.
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Resumen
Evidencia sobre los efectos del paracetamol en los nin˜os febriles
La prescripcio´n de antipire´ticos, entre ellos el acetaminofeno
(paracetamol), a los nin˜os con pirexia es una pra´ctica comu´n, pese
a los pocos datos demostrativos de un beneficio clı´nico. Se realizo´
una revisio´n de la literatura buscando en MEDLINE y en las bases de
datos de Cochrane artı´culos de investigacio´n sobre la eficacia del
paracetamol en los nin˜os con enfermedades febriles y sobre las
reacciones adversas asociadas a su uso. Ninguno de los estudios
revelaba que la administracio´n de dosis terape´uticas de
paracetamol a los nin˜os febriles afectados por infecciones virales
o bacterianas o con malaria tuviera efectos beneficiosos. Algunos
estudios llevan a pensar que la fiebre podrı´a tener una funcio´n
beneficiosa en las infecciones, pero no se han hecho estudios
prospectivos definitivos en nin˜os para probar tal cosa. Las dosis
terape´uticas de paracetamol son por lo general seguras, aunque se
han dado casos de hepatotoxicidad en nin˜os con las dosis
recomendadas. En los paı´ses en desarrollo donde la malnutricio´n es
comu´n, faltan datos sobre la seguridad del paracetamol. El costo de
este medicamento para las familias pobres es sustancial. No hay
ningu´n dato que indique que el tratamiento de los nin˜os febriles
con paracetamol tenga efectos beneficiosos. El fa´rmaco debe
administrarse u´nicamente a los nin˜os con claros sı´ntomas de
malestar o con enfermedades reconocidamente dolorosas. Es
necesario esclarecer la accio´n del paracetamol en los nin˜os febriles
que padecen malaria grave o septicemia o que esta´n malnutridos.
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Commentary
Fever and antipyresis
Heinz F. Eichenwald1
Whether fever represents a beneficial or harmful response to
infection has been debated for hundreds of years. The issue is
clouded by a common misunderstanding that fever is the
reason an individual with infection feels ill: often once the
elevated body temperature abates, the patient feels better. It is
assumed therefore that reducing the fever would improve the
patient’s condition and shorten their illness. From there, it is
only a short step to conceive of the fever as the illness itself.
Although this logical fallacy remains attractive to medical
personnel and patients, what evidence exists that fever is harmful
or beneficial to the course of an infectious illness? At first glance,
studies to answer the question seem simple to perform.
Unfortunately, however, to investigate the problem directly is
virtually impossible, because every method available to reduce
fever has secondary metabolic consequences: antipyretics affect
the body in many ways, and even physical methods — such as
sponging with cold water — result in a wide range of responses,
including shivering and stimulation of the adrenal–cortical axis.
We thus must seek other lines of evidence — ranging from
teleology and comparative zoology through detailed clinical
observation of defined cases to molecular biology.
Perhaps the most powerful arguments to support a
beneficial effect of fever on infection come from teleology and
genetics. Fever is established as a phylogenetically ancient host
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response that is conserved highly in all mammals (1). That fever,
despite high metabolic and nutritional costs, is conserved so
highly argues forcefully for its evolutionary value, as does the
endogenous nature of its mechanism, which requires a complex
series of steps and interactions. Recent work on the biology of
cytokines has enabled the effects of individual components of
this response — all of which are beneficial to the host — to be
examined. It is reasonable to argue on the basis on the many
similarities in the febrile response and its mechanism among
different vertebral classes, that fever is an adaptive benefit to the
host — despite the fact that it is an energy-expensive
phenomenon. Our inability to demonstrate directly the
beneficial effects of fever in the intact vertebral host because
of the diverse metabolic effects of antipyresis means that this
evolutionary evidence is probably the best we have.
Some support for fever comes from comparative biology.
Cold-blooded animals such as lizards lack a mechanism to
produce fever when they become infected. A ‘‘heat-seeking’’
instinct has been described in these creatures, however; this
allows them to raise their body temperature by external means:
the animals find the warmest spot in the environment and
remain there while their body temperature increases in response
to the external stimulus. The survival value of such behaviour
has been shown clearly in the laboratory.
A question often raised about the evolutionary argument
is why fever would be beneficial in mild to moderately severe
infections but demonstrably deleterious in fulminant disease
(2). Such a difference can be explained by the fact that
evolution has no interest in the preservation of the individual,
only in preserving the species: recovery of many individuals
withmild tomoderately severe infections is farmore important
than the survival of the occasional case of fulminant illness.
As Russell et al. point out, it has proved difficult to show
an unequivocal effect from reducing fever as part of the
treatment of infection. As mentioned, to undertake such
studies is a daunting task — because a beneficial effect
predictably would be found primarily in mild to moderately
severe disease, end-points are impossible to select. Obviously
the duration of fever cannot be one endpoint, but what other
sign or symptom can be objectively and quantitatively
measured in a reproducible manner? Hundreds and probably
thousands of patients would have to be enrolled in double-
blind, placebo-controlled studies and followed in exquisite
detail. This is why so little clinical data are available, and it
seems unlikely that more will be obtained. The information
summarized by Russell et al., however, does seem to support
the conclusion that reducing fever in mild infection can
adversely influence the course of at least some illnesses.
On the other hand, good evidence supports the view that
the high fevers encountered in septic states are deleterious to
the host and that their suppression is helpful in assuring
survival (2). As pointed out earlier, these instances are
comparatively rare, and from an evolutionary perspective all
of the affected individuals would have died.
In addition to the probability that antipyretics may prolong
the course of mild to moderate infectious illnesses, what other
deleterious effects might they have? Russell et al. point out that
little is known about the pharmacokinetics of these drugs in
poorly or malnourished children. Even in developed countries,
all available methods of antipyresis must be treated with respect.
Warning labels became required for paracetamol recently and for
aspirin in the more distant past. In addition to acute poisoning,
the former has been implicated in the development of chronic
renal disease, and perhaps liver failure, when repeatedly
administered over prolonged periods of time (3). Perhaps more
important is the fact that antipyretics mask symptoms or signs;
children with pneumonia, for example, may not receive a proper
diagnosis because their respiratory rate decreases (4) or because,
when the body temperature starts to fall, the child may be
considered to be on the way to recovery and thus needing no
further observation. Finally, of course, the costs may consume a
significant amount of resources that, in developing countries,
could be better devoted to specific diagnosis and therapy.
Other potential benefits of reducing fever are sometimes
cited to justify the use of antipyresis. A common assumption is
that these drugsmake patients feel better, but no clear evidence
shows that this is so. Parents and physicians consistently
cannot distinguish between the effects of placebo and
paracetamol inmost circumstances (5). Perhaps the exceptions
are conditions accompanied by pain, for which the analgesic
effects of the medication provide the benefit. When fevers rise
above 39.5 oC, a reduction in body temperature is sometimes
accompanied by an improvement in subjective symptoms, but
this is inconstant, with young children seeming to benefit more
than older children (6).
The major problem when evaluating the subjective
effects of antipyretics is that they have an enormous placebo
value— as various studies have shown (5, 6). Despite the firm
belief in the effects of antipyretics, children do not feel any
better, eat better, or become more active after their use than
they do after they receive placebo. The argument that the use
of antipyretics reduces the occurrence of febrile seizures also is
not based on evidence: no studies have shown this to be true.
Even in children with previous febrile seizures, the use of
antipyretics has not been helpful (7). Some physicians believe
that the response to antipyretics can be used to differentiate
between bacterial and viral infections, with the latter
respondingmore completely and promptly. Numerous studies
have shown this to be a fallacy (8, 9).
In summary, what does the evidence seem to indicate?
Fever represents a universal, ancient, and usually beneficial
response to infection, and its suppression under most
circumstances has few, if any, demonstrable benefits. On the
other hand, some harmful effects have been shown to occur as a
result of suppressing fever: in most individuals, these are slight,
but when translated to millions of people, they may result in an
increase in morbidity and perhaps the occurrence of occasional
mortality. It is clear, therefore, that widespread use of
antipyretics should not be encouraged either in developing
countries or in industrial societies. Unfortunately though, just as
fever represents an ancient biological response, an emotional
effect is embedded deeply. Through the ages, parents have seen
that when fever begins to diminish and disappears, the child feels
better and recovers from the illness — whatever it was. Thus,
the fever has become synonymous with the illness. This flaw in
logic has persisted in parents’ and physicians’minds, and they are
seduced by the thought that if they ‘‘make the fever go away, the
patient will be well.’’ No amount of scientific discourse will
change this attitude, and antipyresis will continue to be used in
children with low-grade fevers, or even no fevers, in the home as
well as the hospital. A reasonable evidence-based approach is to
discourage the use of antipyretics in fevers <39 oC, reserving
them for patients with higher temperatures. n
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